10-Q: Drugs Made in America Acquisition Corp. Q1 2026 Update

Drugs Made in America Acquisition Corp. reports Q1 2026 net income of $1.97 million, driven by trust account interest, while continuing its search for a business combination.

Summary

• Drugs Made in America Acquisition Corp. (DMAA) reported a net income of $1,970,459 for the first quarter ended March 31, 2026.
• This income was primarily generated from interest earned on its Trust Account, totaling $2,113,760.
• Operating expenses, mainly general and administrative costs, were $143,301 for the quarter.
• The company's cash position increased to $14,887 from $6,137 at the end of the previous year.
• The Trust Account balance stood at $242,020,416 as of March 31, 2026.
• DMAA continues its search for a business combination, with a focus on the pharmaceutical industry.
• The company extended its combination period to April 29, 2027, with the sponsor depositing $300,000 to facilitate this extension.
• A significant number of shareholders (9,440,230 shares) redeemed their shares, totaling $99,336,017, following an extension meeting.
• A definitive merger agreement was entered into with Power Analytics Global Corp. (PAGC) on April 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, with positive developments like the merger agreement offset by significant shareholder redemptions and identified control weaknesses.

Positives

• Generated a net income of $1,970,459 for the quarter, primarily from interest income on the Trust Account.
• The Trust Account balance remains substantial at $242,020,416, providing a strong foundation for a business combination.
• The company successfully extended its business combination deadline to April 29, 2027, with sponsor support.
• Entered into a definitive merger agreement with Power Analytics Global Corp. (PAGC) on April 29, 2026, indicating progress towards a business combination.

Negatives

• The company has a working capital deficit of $477,282 as of March 31, 2026.
• Significant shareholder redemptions totaling $99,336,017 occurred, reducing the funds available for a business combination.
• The Sponsor has acknowledged an inability to fulfill financial and operational obligations typically associated with a sponsor role.
• Material weaknesses in internal controls were identified, including inadequate segregation of duties and lack of formal review processes for related party transactions.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to its incurred costs, pursuit of acquisition plans, and the mandatory liquidation date.
• The company has not yet commenced operations and will not generate operating revenues until after the completion of its initial business combination.
• There is no assurance that the company will be able to complete a business combination successfully within the extended Combination Period.
• Geopolitical events such as the conflicts in Ukraine and the Middle East, and resulting market volatility, could adversely affect the company's ability to complete a business combination.
• The company is subject to risks associated with early-stage and emerging growth companies.
• The company's disclosure controls and procedures were found to be not effective due to material weaknesses.

Future Outlook

The company is actively seeking a business combination, with a definitive merger agreement signed with Power Analytics Global Corp. The company has extended its deadline to complete a business combination to April 29, 2027. Management plans to address going concern uncertainties through a successful business combination.

Management Comments

• The company's management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
• Management plans to address the uncertainty regarding the company's ability to continue as a going concern through a Business Combination.
• The company's management has identified material weaknesses in the design and operation of disclosure controls and procedures.

Industry Context

StockSavvy.ai notes that Drugs Made in America Acquisition Corp. is a special purpose acquisition company (SPAC) focused on the pharmaceutical industry, a sector that has seen significant activity in SPAC mergers, though market conditions and regulatory scrutiny have impacted the landscape.

Comparison to Industry Standards

• As a SPAC, direct comparison to traditional operating companies on metrics like revenue or profit is not applicable. Its primary benchmark is the successful completion of a business combination within its mandated timeframe.
• The extension of the combination period to April 29, 2027, is a common strategy for SPACs facing market challenges or seeking more time to identify a suitable target, though it increases the risk of liquidation if a combination is not achieved.
• The significant shareholder redemptions (approximately $99.3 million) are a notable factor, impacting the capital available for the target company post-merger. This level of redemption is not uncommon in the current SPAC market, where investor confidence can fluctuate.

Corporate Governance

Legal Proceedings

• To the knowledge of management, there is no litigation currently pending against the company, its officers, or directors.

Related Party Transactions

• The Sponsor, Drugs Made In America Acquisition LLC, purchased Private Placement Units.
• The Sponsor has provided working capital loans under a subscription promissory note.
• The Sponsor has paid expenses on behalf of the Company.
• An administrative services agreement was in place with the Sponsor (cancelled in March 2026).
• A promissory note from the Sponsor was repaid in connection with the IPO.
• The Company entered into a consulting agreement with Titan Advisory Services LLC, an affiliate of the new CFO, Saleem Elmasri.
• The Company entered into a compensation agreement with Aleutian Equity Holdings LLC, an affiliate of the CEO, Roger E. Bendelac.
• The Company issued an interim convertible note to BV Advisory Partners, LLC, which is related to a potential financing transaction.

Stakeholder Impact

• Shareholders: Significant redemptions by public shareholders reduce the capital available for the business combination. Remaining shareholders will be impacted by the success of the merger with PAGC.
• Sponsor: The Sponsor has acknowledged inability to fulfill typical sponsor obligations and has had share subscription receivable reduced to zero. Their role and future involvement may be limited.
• Creditors: The company has a working capital deficit, and its ability to meet obligations is dependent on a successful business combination.
• Management: Management is focused on completing a business combination and has disclosed material weaknesses in internal controls that need to be addressed.

Next Steps

• Complete the business combination with Power Analytics Global Corp. (PAGC).
• The company has extended its combination period to April 29, 2027.
• The sponsor is required to deposit funds for each monthly extension of the combination period.
• Address material weaknesses in internal controls.

Key Dates

Recommendation

The company has a definitive merger agreement with PAGC, which is a positive step. However, significant shareholder redemptions, the sponsor's reduced capacity, and identified material weaknesses in internal controls warrant a cautious 'hold' stance until the business combination is closer to completion and control issues are addressed.

Keywords

Drugs Made in America Acquisition Corp., Form 10-Q, Quarterly Report, SPAC, Business Combination, Trust Account, Merger Agreement, Power Analytics Global Corp., Pharmaceutical Industry, Financial Statements